Chronic Spontaneous Urticaria Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Chronic Spontaneous Urticaria Market By 2029?

The chronic spontaneous urticaria market has experienced substantial growth in recent years. It is anticipated to expand from $2.06 billion in 2024 to $2.23 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.3%. The market’s past growth can be ascribed to advancements in diagnostic tools, increased awareness within the healthcare community, the contributions of patient advocacy and support groups, ongoing research and clinical trials exploring novel therapies, and a rise in healthcare expenditure.

The chronic spontaneous urticaria market is projected to experience substantial expansion over the upcoming years, reaching $3.01 billion by 2029, driven by a compound annual growth rate (CAGR) of 7.9%. This anticipated growth during the forecast period is due to factors such as a rise in diagnosed CSU cases, an expanding patient population, improvements in healthcare infrastructure, a supportive regulatory landscape, the adoption of patient-centric care models, and economic progress in developing markets. Key developments expected during this period involve technological innovations, breakthroughs in biological therapies, personalized medical approaches, the widespread use of telemedicine and digital health, sophisticated diagnostic instruments, the application of AI and machine learning, and an increase in drug approvals and new product introductions.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which Drivers Are Impacting The Chronic Spontaneous Urticaria Market?

Elevated alcohol intake is projected to fuel expansion in the chronic spontaneous urticaria market in the future. This uptick in alcohol intake stems from multiple elements, including societal standards, pressure, promotional activities, cost-effectiveness, and ease of access. For certain people, ingesting alcohol might worsen chronic spontaneous urticaria symptoms, resulting in more pronounced hives and edema. As an illustration, data from February 2024 by rehabs.UK, a UK entity offering addiction recovery aid, indicated that 55% of men consumed alcohol weekly, in contrast to 41% of women. Furthermore, close to daily alcohol consumption was reported by 8% of men, versus 5% of women. Between 2021 and 2022, hospitalizations solely due to alcohol reached 342,795, which equates to a rate of 626 admissions per 100,000 individuals. Consequently, the growing trend of alcohol consumption is a key factor propelling the expansion of the chronic spontaneous urticaria market.

What Are The Segment Types Shaping The Chronic Spontaneous Urticaria Market?

The chronic spontaneous urticariamarket covered in this report is segmented –

1) By Treatment: Medication; Phototherapy; Other Treatments

2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration

3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Medication: Antihistamines; Leukotriene Receptor Antagonists; Monoclonal Antibodies; Immunosuppressants; Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy; UVA Phototherapy; Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies; Dietary Modifications; Psychotherapy (for Stress-Related Triggers)

How Are Emerging Market Trends Shaping The Chronic Spontaneous Urticaria Industry Landscape?

Leading companies in the chronic spontaneous urticaria market are developing advanced next-generation Briquilimab (JSP191) with the goal of improving treatment effectiveness and reducing how often doses are administered. Next-generation Briquilimab (JSP191) is defined as a monoclonal antibody created to specifically target and deplete certain immune cells, particularly those expressing CD47, which are relevant in conditions like chronic spontaneous urticaria. As an illustration, in November 2023, Jasper Therapeutics Inc., a US-based clinical-stage biotechnology company, announced the dosing of its first patient in a Phase 1b/2a clinical study of Briquilimab for chronic spontaneous urticaria (CSU). This achievement marks a crucial step in evaluating the safety and efficacy of Briquilimab, a next-generation monoclonal antibody that targets CD47, in managing this recurring problem of hives and itching. The study aims to assess Briquilimab’s potential to alleviate symptoms and enhance the quality of life for patients suffering from CSU.

Who Are The Prominent Global Companies Shaping The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Regional Markets Are Contributing Most To The Chronic Spontaneous Urticaria Industry Expansion?

North America was the largest region in the chronic spontaneous urticaria market in 2024. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Spontaneous Urticaria Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2025, By The Business Research Company

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795